[et_pb_section fb_built=”1″ admin_label=”Submen\u00fc” _builder_version=”4.27.4″ _module_preset=”default” background_color=”#7F5E75″ custom_margin=”0px||0px||false|false” custom_padding=”0px||0px||false|false” sticky_position=”top” sticky_position_tablet=”none” sticky_position_phone=”none” sticky_position_last_edited=”on|phone” locked=”off” collapsed=”off” global_colors_info=”{}”][et_pb_row _builder_version=”4.27.4″ _module_preset=”default” custom_padding=”10px||10px||false|false” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font=”Georgia||||||||” text_text_color=”#FFFCFC” text_font_size=”16px” link_text_color=”#FFFCFC” text_orientation=”center” global_colors_info=”{}”]<\/p>\n
WID\u00ae-easy<\/a> | WID\u00ae-can<\/a><\/p>\n [\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.27.4″ _module_preset=”default” background_color=”#FFFCFC” collapsed=”on” global_colors_info=”{}”][et_pb_row _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.22.1″ _module_preset=”default” global_colors_info=”{}”][et_pb_heading title=”Our Research” _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_heading][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]<\/p>\n Sola Diagnostics is dedicated to developing innovative epigenetic diagnostics for cancer in women using vaginal swabs.<\/p>\n Sola Diagnostics licenses technologies whose research was started by Prof. Dr. Martin Widschwendter at University College London in the late 1990s and is now being continued at the EUTOPS Institute at the University of Innsbruck<\/a>.<\/p>\n A complete list of scientific publications can be found here<\/a>.<\/p>\n [\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ admin_label=”Divider” _builder_version=”4.27.4″ _module_preset=”default” background_color=”#fffcfc” locked=”off” collapsed=”on” global_colors_info=”{}”][et_pb_row _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_divider _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_divider][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ admin_label=”section – Prof. Widschwendter” _builder_version=”4.27.4″ background_color=”#FFFCFC” locked=”off” collapsed=”on” global_colors_info=”{}”][et_pb_row column_structure=”1_2,1_2″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_2″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_heading title=”Prof Dr Martin Widschwendter” _builder_version=”4.27.4″ _module_preset=”default” title_level=”h2″ custom_padding=”27px||||false|false” global_colors_info=”{}”][\/et_pb_heading][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n Prof Dr Martin Widschwendter<\/a> is a gynecologic oncologist and pioneer in the field of primary and secondary prevention of gynecologic cancer using epigenetic DNA methylation makers.<\/p>\n He is head of the EUTOPS Institute at the University of Innsbruck<\/a>, a professor at University College London and holds a visiting professorship at the Karolinska Institute in Stockholm.<\/p>\n [\/et_pb_text][\/et_pb_column][et_pb_column type=”1_2″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/sola-diagnostics.com\/wp-content\/uploads\/2023\/10\/foto_widschwendter.jpg__1200.0x720_q85_crop_subsampling-2_upscale-removebg-preview.png” title_text=”foto_widschwendter.jpg__1200.0x720_q85_crop_subsampling-2_upscale-removebg-preview” url=”https:\/\/www.linkedin.com\/in\/martin-widschwendter-66453b3b\/” url_new_window=”on” align=”center” _builder_version=”4.27.4″ _module_preset=”default” width=”80%” max_width=”100%” max_width_tablet=”100%” max_width_phone=”100%” max_width_last_edited=”on|phone” module_alignment=”center” custom_margin=”||||false|false” filter_saturate=”70%” global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”||||false|false” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.22.1″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/sola-diagnostics.com\/wp-content\/uploads\/2023\/09\/Universitaten-Logos.png” title_text=”Universities logos” _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_image][et_pb_heading title=”Scientific milestones of Prof Widschwendter” _builder_version=”4.27.4″ _module_preset=”default” title_level=”h3″ global_colors_info=”{}”][\/et_pb_heading][et_pb_accordion _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_accordion_item title=”1997 – Epigenetic Field Cancerization” open=”on” open_toggle_text_color=”#504756″ open_toggle_background_color=”#FFFCFC” closed_toggle_background_color=”#D9BACB” icon_color=”#7F5E75″ toggle_icon=”G||divi||400″ use_icon_font_size=”on” icon_font_size=”22px” _builder_version=”4.27.4″ _module_preset=”default” background_color=”#FFFCFC” background_enable_color=”on” border_width_all=”2px” border_color_all=”#7F5E75″ global_colors_info=”{}” toggle_text_color=”#504756″ toggle_level=”h4″ toggle_font=”||||||||” toggle_letter_spacing=”1px”]<\/p>\n Widschwendter M<\/span>, Berger J, Daxenbichler G, M\u00fcller-Holzner E, Widschwendter A, Mayr A, Marth C, Zeimet AG. Loss of retinoic acid receptor beta expression in breast cancer and morphologically normal adjacent tissue but not in the normal breast tissue distant from the cancer. Cancer Res. (1997); 57:4158-4161. PMID: 9331065<\/a>.<\/em><\/p>\n Widschwendter M<\/span>, Berger J, Hermann M, M\u00fcller HM, Amberger A, Zeschnigk M, Widschwendter A, Abendstein B, Zeimet AG, Daxenbichler G, Marth C. Methylation and silencing of the retinoic acid receptor-beta2 gene in breast cancer. J Natl Cancer Inst. (2000); 92:826-832. PMID: 10814678<\/a>.<\/em><\/p>\n [\/et_pb_accordion_item][et_pb_accordion_item title=”2004 – Epigenetics in Surrogate Tissue (cfDNA)” open_toggle_text_color=”#504756″ open_toggle_background_color=”#FFFCFC” closed_toggle_background_color=”#D9BACB” icon_color=”#7F5E75″ toggle_icon=”G||divi||400″ use_icon_font_size=”on” icon_font_size=”22px” _builder_version=”4.27.4″ _module_preset=”default” background_color=”#FFFCFC” background_enable_color=”on” border_width_all=”2px” border_color_all=”#7F5E75″ global_colors_info=”{}” toggle_text_color=”#504756″ toggle_level=”h4″ toggle_font=”||||||||” toggle_letter_spacing=”1px” open=”off”]<\/p>\n Cancer detection typically requires direct access to the tumor via (often very invasive) sampling methods. We were one of the first who assessed the analysis of cell-free DNAme in serum\/plasma for cancer detection and assessment of minimal residual disease and outcome (examples provided are for breast and cervical cancer).<\/strong><\/p>\n —<\/strong><\/p>\n M\u00fcller HM, Widschwendter A, Fiegl H, Ivarsson L, Goebel G, Perkmann E, Marth C, Widschwendter M<\/span>. DNA methylation in serum of breast cancer patients: an independent prognostic marker. Cancer Res. (2003); 63:7641-7645. PMID: 14633683<\/a>.<\/em><\/p>\n Widschwendter A, Ivarsson L, Blassnig A, M\u00fcller HM, Fiegl H, Wiedemair A, M\u00fcller-Holzner E, Goebel G, Marth C, Widschwendter M<\/span>. CDH1 and CDH13 methylation in serum is an independent prognostic marker in cervical cancer patients. Int J Cancer. (2004); 109:163-166. PMID: <\/span>14750164<\/a><\/em><\/p>\n [\/et_pb_accordion_item][et_pb_accordion_item title=”2004 – Epigenetics for Colorectal Cancer (i.e. fecal sample)” open_toggle_text_color=”#504756″ open_toggle_background_color=”#FFFCFC” closed_toggle_background_color=”#D9BACB” icon_color=”#7F5E75″ toggle_icon=”G||divi||400″ use_icon_font_size=”on” icon_font_size=”22px” _builder_version=”4.27.4″ _module_preset=”default” background_color=”#FFFCFC” background_enable_color=”on” border_width_all=”2px” border_color_all=”#7F5E75″ global_colors_info=”{}” toggle_text_color=”#504756″ toggle_level=”h4″ toggle_font=”||||||||” toggle_letter_spacing=”1px” open=”off”]<\/p>\n We were the first to assess whether DNA methylation in stool samples is able to detect colorectal cancer.<\/strong><\/p>\n —<\/strong><\/p>\n M\u00fcller HM, Oberwalder M, Fiegl H, Morandell M, Goebel G, Zitt M, M\u00fchlthaler M, Ofner D, Margreiter R, Widschwendter M<\/span>. Methylation changes in faecal DNA: a marker for colorectal cancer screening? Lancet. (2004); 363:1283-1285. PMID: 15094274<\/a>.<\/em><\/p>\n [\/et_pb_accordion_item][et_pb_accordion_item title=”2004 – Epigenetics in Self-Sampled Cervico-Vaginal Fluid” open_toggle_text_color=”#504756″ open_toggle_background_color=”#FFFCFC” closed_toggle_background_color=”#D9BACB” icon_color=”#7F5E75″ toggle_icon=”G||divi||400″ use_icon_font_size=”on” icon_font_size=”22px” _builder_version=”4.27.4″ _module_preset=”default” background_color=”#FFFCFC” background_enable_color=”on” border_width_all=”2px” border_color_all=”#7F5E75″ global_colors_info=”{}” toggle_text_color=”#504756″ toggle_level=”h4″ toggle_font=”||||||||” toggle_letter_spacing=”1px” open=”off”]<\/p>\n Our early studies showed the potential of samples of fluid from the vagina for early cancer detection. We showed that DNA methylation of a few regions in a sample of vaginal fluid collected on a tampon is able to identify women with endometrial or cervical cancer.<\/strong><\/p>\n —<\/strong><\/p>\n Fiegl H, Gattringer C, Widschwendter A, Schneitter A, Ramoni A, Sarlay D, Gaugg I, Goebel G, M\u00fcller HM, Mueller-Holzner E, Marth C, Widschwendter M<\/span>. Methylated DNA collected by tampons–a new tool to detect endometrial cancer. Cancer Epidemiol Biomarkers Prev. (2004); 13:882-888. PMID: 15159323<\/a>.<\/em><\/p>\n Widschwendter A, Gattringer C, Ivarsson L, Fiegl H, Schneitter A, Ramoni A, M\u00fcller HM, Wiedemair A, Jerabek S, M\u00fcller-Holzner E, Goebel G, Marth C, Widschwendter M<\/span>. Analysis of aberrant DNA methylation and human papillomavirus DNA in cervicovaginal specimens to detect invasive cervical cancer and its precursors. Clin Cancer Res. (2004); 10:3396-3400. PMID: 15161694<\/a>.<\/em><\/p>\n [\/et_pb_accordion_item][et_pb_accordion_item title=”2007 – PCGT-Methylation Cellular Aging and Cancer” open_toggle_text_color=”#504756″ open_toggle_background_color=”#FFFCFC” closed_toggle_background_color=”#D9BACB” icon_color=”#7F5E75″ toggle_icon=”G||divi||400″ use_icon_font_size=”on” icon_font_size=”22px” _builder_version=”4.27.4″ _module_preset=”default” background_color=”#FFFCFC” background_enable_color=”on” border_width_all=”2px” border_color_all=”#7F5E75″ global_colors_info=”{}” toggle_text_color=”#504756″ toggle_level=”h4″ toggle_font=”||||||||” toggle_letter_spacing=”1px” open=”off”]<\/p>\n We pioneered the concept that aberrant DNA methylation at gene promoter sites, which are (reversibly) occupied by the Polycomb Repressor Complex 2 in stem cells, are heavily methylated in cancer. This paper was the first to support the concept that blocking the differentiation of stem cells due to epigenetic mechanisms is one of the key contributing factors to cancer formation. Describe the concept that these Polycomb Group Target Genes (PCGTs) lock stem cells in an undifferentiated status and thereby predispose these cells to cancer transformation. Our later and ongoing studies demonstrate that methylation of these PCGT regions is triggered by age, cell replication and by various exposures like smoking.<\/strong><\/p>\n —<\/strong><\/p>\n Widschwendter M<\/span>, Fiegl H, Egle D, Mueller-Holzner E, Spizzo G, Marth C, Weisenberger DJ, Campan M, Young J, Jacobs I, Laird PW. Epigenetic stem cell signature in cancer. Nat Genet. (2007); 39:157-158. PMID: 17200673<\/a>.<\/em><\/p>\n [\/et_pb_accordion_item][et_pb_accordion_item title=”2009 – EWAS – Epigenome Wide Association Studies” open_toggle_text_color=”#504756″ open_toggle_background_color=”#FFFCFC” closed_toggle_background_color=”#D9BACB” icon_color=”#7F5E75″ toggle_icon=”G||divi||400″ use_icon_font_size=”on” icon_font_size=”22px” _builder_version=”4.27.4″ _module_preset=”default” background_color=”#FFFCFC” background_enable_color=”on” border_width_all=”2px” border_color_all=”#7F5E75″ global_colors_info=”{}” toggle_text_color=”#504756″ toggle_level=”h4″ toggle_font=”||||||||” toggle_letter_spacing=”1px” open=”off”]<\/p>\n Widschwendter M<\/span>, Apostolidou S, Raum E, Rothenbacher D, Fiegl H, Menon U, Stegmaier C, Jacobs IJ, Brenner H. Epigenotyping in peripheral blood cell DNA and breast cancer risk: a proof of principle study. PLoS One (2008 Jul 16); 3(7):e2656. PMID: 18628976<\/a>.<\/em><\/p>\n [\/et_pb_accordion_item][et_pb_accordion_item title=”2008 – Tissue Specificity of the Epigenome” open_toggle_text_color=”#504756″ open_toggle_background_color=”#FFFCFC” closed_toggle_background_color=”#D9BACB” icon_color=”#7F5E75″ toggle_icon=”G||divi||400″ use_icon_font_size=”on” icon_font_size=”22px” _builder_version=”4.27.4″ _module_preset=”default” background_color=”#FFFCFC” background_enable_color=”on” border_width_all=”2px” border_color_all=”#7F5E75″ global_colors_info=”{}” toggle_text_color=”#504756″ toggle_level=”h4″ toggle_font=”||||||||” toggle_letter_spacing=”1px” open=”off”]<\/p>\n This research highlighted the importance of considering the cell-type specificity of the epigenome when utilizing it for disease prediction. We developed a DNAme based risk predictor for ovarian cancer by comparing blood DNA from women with and without active ovarian cancer with a Receiver Operator Characteristic Area Under the Curve significantly in excess of 0.8 in an independent validation set. However, we eventually realized that the actual DNAme profile was a reflection of the increased granulocyte\/lymphocyte ratio which was elevated in women with active ovarian cancers and not an indicator of future risk.<\/strong><\/p>\n —<\/strong><\/p>\n Teschendorff AE. Menon U, Gentry-Maharaj A, Ramus SJ, Gayther SA, Apostolidou S, Jones A, Lechner M, Beck S, Jacobs IJ & Widschwendter M<\/span>. An epigenetic signature in peripheral blood predicts active ovarian cancer. PLoS One. (2009 dec); 4(12), e8274. PMID: 20019873<\/a>.<\/em><\/p>\n [\/et_pb_accordion_item][et_pb_accordion_item title=”2018 – Cancer Risk Prediction in Surrogate Tissue” open_toggle_text_color=”#504756″ open_toggle_background_color=”#FFFCFC” closed_toggle_background_color=”#D9BACB” icon_color=”#7F5E75″ toggle_icon=”G||divi||400″ use_icon_font_size=”on” icon_font_size=”22px” _builder_version=”4.27.4″ _module_preset=”default” background_color=”#FFFCFC” background_enable_color=”on” border_width_all=”2px” border_color_all=”#7F5E75″ global_colors_info=”{}” toggle_text_color=”#504756″ toggle_level=”h4″ toggle_font=”||||||||” toggle_letter_spacing=”1px” open=”off”]<\/p>\n We were the first to demonstrate that epigenetic footprints in hormone-sensitive cervical cells are a good proxy that best captures the risk for various women-specific cancers, including breast cancer.<\/strong><\/p>\n —<\/strong><\/span><\/p>\n Barrett JE, Herzog C, Jones A, Leavy OC, Evans I, Knapp S, Reisel D, Nazarenko T, Kim Y-N, Franchi D, Ryan A, Franks J, Bj\u00f8rge L, Zikan M, Cibula D, Harbeck N, Colombo N, Dudbridge F, Jones L, Sundstr\u00f6m K, Dillner J, Fl\u00f6ter R\u00e5destad A, Gemzell-Danielsson K, Pashayan N, Widschwendter M<\/span>. The WID-BC-index identifies women with primary poor prognostic breast cancer based on DNA methylation in cervical samples. Nat Commun. (2022 Feb 01); 13(1):449. doi: 10.1038\/s41467-021-27918-w<\/a>. PMID: 35105882<\/a>.<\/em><\/p>\n [\/et_pb_accordion_item][et_pb_accordion_item title=”2022 – Epigenetics Monitoring for Primary Prevention of Breast Cancer” open_toggle_text_color=”#504756″ open_toggle_background_color=”#FFFCFC” closed_toggle_background_color=”#D9BACB” icon_color=”#7F5E75″ toggle_icon=”G||divi||400″ use_icon_font_size=”on” icon_font_size=”22px” _builder_version=”4.27.4″ _module_preset=”default” background_color=”#FFFCFC” background_enable_color=”on” border_width_all=”2px” border_color_all=”#7F5E75″ global_colors_info=”{}” toggle_text_color=”#504756″ toggle_level=”h4″ toggle_font=”||||||||” toggle_letter_spacing=”1px” open=”off”]<\/p>\n We describe the potential for individualized breast cancer prevention and risk monitoring using antiprogestins and a novel type of epigenetic test, the WID-Breast29. Our findings may be particularly valuable for individuals at the highest risk, for instance, BRCA mutation carriers.<\/strong><\/p>\n —<\/strong><\/p>\n Bartlett TE, Evans I, Jones A, Barrett JE, Haran S, Reisel D, \u2026 Howell SJ, Risques RA, Fl\u00f6ter R\u00e5destad A, Dubeau L, Gemzell-Danielsson K, Widschwendter M<\/span>. Antiprogestins reduce epigenetic field cancerization in breast tissue of young healthy women. Genome Med. (2022 Jun 15); 14(1):64. doi: 10.1186\/s13073-022-01063-5<\/a>. PMID: <\/span>35701800<\/a><\/em><\/p>\n [\/et_pb_accordion_item][\/et_pb_accordion][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":" WID\u00ae-easy | WID\u00ae-canSola Diagnostics is dedicated to developing innovative epigenetic diagnostics for cancer in women using vaginal swabs. Sola Diagnostics licenses technologies whose research was started by Prof. Dr. Martin Widschwendter at University College London in the late 1990s and is now being continued at the EUTOPS Institute at the University of Innsbruck. A complete […]<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"class_list":["post-258207","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/sola-diagnostics.com\/en\/wp-json\/wp\/v2\/pages\/258207","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sola-diagnostics.com\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/sola-diagnostics.com\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/sola-diagnostics.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/sola-diagnostics.com\/en\/wp-json\/wp\/v2\/comments?post=258207"}],"version-history":[{"count":0,"href":"https:\/\/sola-diagnostics.com\/en\/wp-json\/wp\/v2\/pages\/258207\/revisions"}],"wp:attachment":[{"href":"https:\/\/sola-diagnostics.com\/en\/wp-json\/wp\/v2\/media?parent=258207"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}